DUBLIN, IRELAND, July 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 first quarter results at 9:00 a.m. ET on August 7, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after ...

Pre-market futures are inching higher once again this morning. We are devoid major economic reports ahead of today’s open, but have plenty of quarterly earnings results, as you can see below. The Dow and the S&P 500 are both currently up +9 points, while the Nasdaq is +4 points. Bond yields continue to shrink away: +4.36% on the 10-year, +3.84% on the 2-year, and it look like we’ll once again stop talking about the 30-year bond yield, which is down to +4.94%.Biggest Q2 Earnings Morning Thus FarSo many impor ...

Steris (STE) has been on a downward spiral lately with significant selling pressure. After declining 6% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator th ...

Key Takeaways DHR's Life Sciences segment's revenues are likely to drop 3.4% on weak demand in key end markets. Diagnostics performance is expected to be hurt by soft molecular test demand and lower China sales. Biotechnology revenues are projected to rise 7% on strong bioprocessing and discovery business demand.Danaher Corporation (DHR) is scheduled to release second-quarter 2025 results on July 22, before market open.The Zacks Consensus Estimate for revenues is pegged at $5.84 billion, which indicates a ...

Core Insights - The report titled "Siemens: 360 Company Analysis" provides a comprehensive overview of Siemens, detailing its history, product offerings, technologies, and financial performance over the past three years [1][4]. Group 1: Company Overview - Siemens specializes in power generation and distribution, automation, digitalization, smart infrastructure, and distributed energy systems [2]. - The company holds over 41,700 granted patents globally and was the top-ranked company in patent applications at the European Patent Office in 2024, with 1,830 applications [2]. Group 2: Business Segments - Siemens operates through five business segments: digital industries, Siemens Healthineers, smart infrastructure, mobility, and Siemens Financial Services [3]. - The digital industries segment offers a wide range of automation products and system solutions, including drives, inverters, servo motors, and integrated automation systems [3]. Group 3: Strategic Analysis - The strategic analysis chapter covers recent developments such as mergers, acquisitions, partnerships, product launches, and R&D expenditure from 2022 to 2024, highlighting key focus areas and technological breakthroughs [4]. - A SWOT analysis is included to evaluate the micro and macro environment affecting Siemens' growth trajectory [4]. Group 4: Financial Reporting - The report includes a financial outlook for Siemens over the last three fiscal years, detailing key financial parameters and performance across business and geographic segments [9][13]. Group 5: Corporate Social Responsibility (ESG) - An overview of sustainability trends and ESG developments is provided, outlining Siemens' initiatives and strategies in environmental, social, and governance aspects [10][13].

SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2025 after the close of trading on Wednesday, August 6, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Offic ...

Core Insights - Johnson & Johnson's shares increased by 6.1% following the release of earnings that exceeded expectations and an upward revision of full-year guidance [1] Financial Performance - In the second quarter, Johnson & Johnson reported a revenue growth of 5.8%, reaching $23.7 billion, surpassing analyst expectations [2] - Adjusted earnings per share (EPS) were $2.77, a decline of 1.8% year-over-year, but still above analysts' forecasts [2] Cost and Tariff Impact - The decline in earnings was attributed to increased cost of goods sold, including amortization from the $14.6 billion acquisition of Intra-Cellular Therapies, which closed on April 2 [3] - Management anticipates a $200 million impact from tariffs this year, reduced from an earlier estimate of $400 million [3] Segment Growth - The Neuroscience unit experienced a 14.4% year-over-year growth in constant currency, aided by the Intra-Cellular acquisition, while the oncology segment grew by 22.3% [4] Revised Guidance - Management raised its full-year revenue guidance to a range of $93.2 billion to $93.6 billion and adjusted EPS guidance to $10.80 to $10.90, compared to previous guidance of $91 billion to $91.8 billion and $10.50 to $10.70 [4] Investment Perspective - Johnson & Johnson is positioned as a leading blue-chip pharmaceutical and medtech company, with a current valuation of 15 times the new earnings guidance and a dividend yield of 3.4%, making it attractive for income-oriented investors [6]

Core Insights - Jin Medical International Ltd. has launched production at its new intelligent manufacturing facility in Chuzhou, Anhui, China, aiming to enhance its rehabilitation medical equipment supply chain [1][2] - The facility is equipped to produce 200,000 units annually, adhering to Japanese Industrial Standards (JIS) for quality [2] - Jin Medical's product range includes ultra-light wheelchairs, competition-grade equipment, micro hyperbaric oxygen chambers, and beauty devices, reflecting a commitment to meet diverse health needs [3] Company Overview - Founded in 2006, Jin Medical is headquartered in Changzhou, Jiangsu Province, China, and specializes in designing, developing, and manufacturing products for rehabilitation and elderly care [6] - The company operates two existing manufacturing plants totaling approximately 230,000 square feet and is establishing a new facility of 430,000 square feet in Chuzhou [6] - Jin Medical collaborates with over 40 distributors in China and more than 20 international distributors, primarily selling its wheelchair products in Japan and China [6] Strategic Vision - The CEO of Jin Medical emphasized a shift in rehabilitation technology towards enhancing quality of life, leveraging intelligent manufacturing to meet global health demands [4] - The company is actively testing new electric wheelchairs for distribution in senior care communities and rehabilitation centers across various international locations [4] - Jin Medical aims to bridge the gap between East and West in rehabilitation technology, positioning itself for future growth on the global stage [5]

Core Viewpoint - Haemonetics Corporation will release its first quarter fiscal year 2026 financial results on August 7, 2025, and will hold a conference call for discussion with investors and analysts [1][2]. Company Information - Haemonetics is a global medical technology company focused on enhancing healthcare quality, effectiveness, and efficiency through innovative solutions [3]. - The company offers a range of technologies for hospitals, plasma collection centers, and blood centers to improve patient outcomes and operational efficiency [3]. Investor Relations - The conference call will take place at 8:00 am ET on August 7, 2025, with access available via teleconference and a live webcast on the investor relations website [2]. - A replay of the conference call will be available for one year starting from August 7, 2025 [2][4].

Core Insights - Thermo Fisher Scientific Inc. (TMO) is focused on growth through strategic acquisitions and product launches, while facing challenges from macroeconomic volatility and foreign currency exchange [1][9][10] Financial Performance - TMO's stock has increased by 20.6% over the past year, outperforming the industry which declined by 11.3% and the S&P 500 which gained 10.2% [2] - The company has a market capitalization of $158.1 billion and an earnings yield of 5.3%, significantly higher than the industry's -2.8% [2] - TMO has consistently surpassed earnings estimates over the past four quarters, with an average surprise of 2.3% [2] Growth Strategies - A notable acquisition includes Solventum's Purification & Filtration business for $4.1 billion, expected to enhance TMO's biologics capabilities and deliver $125 million in adjusted operating income synergies over five years [3][7] - The acquisition of Olink has strengthened TMO's position in the high-growth proteomics market [3][7] - Recent product launches include the CorEvitas Adolescent Alopecia Areata Registry and the Invitrogen EVOS S1000 Spatial Imaging System, aimed at addressing specific market needs [4][7] Research and Development - TMO is increasing its R&D investments, with a projected 51.1% rise in R&D expenses for the second quarter of 2025 [5] Financial Health - As of March 29, 2025, TMO has a long-term debt of $31.37 billion, with cash and cash equivalents totaling $5.95 billion, indicating strong liquidity [8] - The times interest earned ratio stands at 6.3%, reflecting stable solvency [8] Macroeconomic Challenges - TMO is facing macroeconomic challenges, including geopolitical tensions and supply chain disruptions, which may impact profitability [9] - The company has experienced a 1% unfavorable effect on revenues in Q1 2025 due to currency translation from a stronger U.S. dollar [10] Earnings Estimates - The Zacks Consensus Estimate for TMO's earnings per share (EPS) has increased to $22.34, with 2025 revenue estimates at $43.71 billion, indicating a 1.9% rise from the previous year [11]